The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors.
A. J. Zurita
No relevant relationships to disclose
J. Heymach
Consultant or Advisory Role - AstraZeneca; Auschon; Boehringer Ingelheim; GlaxoSmithKline; Pfizer
Research Funding - AstraZeneca; GlaxoSmithKline; Pfizer
M. Khajavi
No relevant relationships to disclose
L. Tye
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
X. Huang
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
M. Kulke
Consultant or Advisory Role - Ipsen; Lexicon; Molecular Insight Pharmaceuticals; Novartis; Pfizer
H. Lenz
No relevant relationships to disclose
N. J. Meropol
Research Funding - Pfizer
W. Carley
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer (B)
S. E. DePrimo
No relevant relationships to disclose
C. S. Harmon
Consultant or Advisory Role - Pfizer
Stock Ownership - Pfizer (I)